As-needed ranibizumab dosing may result in undertreatment, significantly less visual gain

This retrospective case series included 124 patients (131 eyes) treated with ranibizumab monotherapy for wet AMD, and followed for at least six months. All patients were treatment naïve. Injections were administered once at baseline and then as-needed, based on clinical evaluation and OCT monitoring. Eyes receiving more frequent injections (<2 month mean interinjection interval) gained more vision (+2.3 lines at 6 months) than eyes receiving injections less frequently. However, resolution of intra- and subretinal fluid on OCT did not correlate with the degree of vision improvement.